If you have a question for our guest, host or DRG please submit it here.
The effects of COVID-19 on worldwide oncology clinical trials
Guest: Steve Fruchtman, President and CEO, Onconova Therapeutics Inc
In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership talks to Steve Fruchtman, President and CEO of Onconova Therapeutics Inc, about how the reallocation of resources within cancer centres around the world due to COVID-19. Steve talked us through the impacts on their early and late stage lead programs which includes short term restrictions such as accessing review data, as well as longer-term impacts including additional monitoring and testing for patients on haematology and oncology trials. Steve gives an insight into how they’re preparing for commercialization of their therapies within China, the affect COVID-19 has had on these partnerships, and how regulatory restrictions and language barriers can present a challenge in this area. Watch the full episode to find out more.
About our Guest
Steve Fruchtman, President and CEO, Onconova Therapeutics Inc
Dr. Fruchtman joined Onconova in January 2015. He has extensive experience in large and small biopharmaceutical companies and has led successful clinical development programs while serving in senior positions at Ortho Biotech Products, Novartis, Allos Therapeutics, Spectrum Pharmaceuticals and Syndax Pharmaceuticals leading to Health Authority approvals for several new chemical entities in various malignancies. Earlier, Dr. Fruchtman was on the faculty of the Mount Sinai School of Medicine and the Director of the Stem Cell Transplantation and Myeloproliferative Disorder Programs at Mount Sinai Hospital in New York City. He is an author of more than 170 lectures, presentations, books, chapters, and abstracts and served as an external reviewer for multiple medical journals. Dr. Fruchtman received his medical degree from New York Medical College with the distinction of membership in the Alpha Omega Alpha honorary medical fraternity. He is currently President and CEO of Onconova Therapeutics.
About our Host
Mike Ward, Head of Thought Leadership, DRG
Mike Ward serves as Global Head of Thought Leadership at Decision Resources Group (DRG), part of Clarivate. As both a journalist and analyst, Mike has been writing, analyzing and commenting on the life sciences industry for more than 35 years. He has held editorial and content leadership roles at various publications and organizations across the industry.